1. Scrip
  2. >>Therapy Areas

Nordic Nanovector Starting Pivotal Trial With Lead Asset Betalutin In R/R FL

 
• By Sten Stovall

Norwegian biotech is starting PARADIGME Phase IIb trial testing Betalutin in follicular lymphoma.

Leukemia cell (blast cell)
Betalutin is a potential new targeted treatment for patients with non-Hodgkin’s lymphoma • Source: Shutterstock

Nordic Nanovector ASA said its pivotal Phase IIb PARADIGME trial with Betalutin in third-line relapsed/refractory follicular lymphoma is now underway and that initial data read-outs are expected in the first-half of 2020 with subsequent filing in 2020 for marketing approval.

The trial will enrol 130 patients at 80-85 sites in around 20 countries, with the first patient set to be dosed in the first half of this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.